Clinical features and comorbidity of mood fluctuations in Parkinson's disease

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 14, Issue 4, 2002, Pages 438-442

  Racette, Brad A ^a   Hartlein, Johanna M ^a   Hershey, Tamara ^a   Mink, Jonathan W ^a   Perlmutter, Joel S ^a   Black, Kevin J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MOOD DISORDER; MOTOR ACTIVITY; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 0036753611     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.14.4.438     Document Type: Article

References (45)

1. Cotzias GC, van Woert HH, Schiffer LM: Aromatic amino acids and modifications of parkinsonism. N Engl J Med 1967; 276:374-379
2. Lees AJ: The on-off phenomenon. J Neurol Neurosurg Psychiatry 1989; 52(suppl):29-37
3. Riley DE, Lang AE: The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993; 43:1459-1464
4. Nissenbaum H, Quinn NP, Brown RG, et al: Mood swings associated with the "on-off" phenomenon in Parkinson's disease. Psychol Med 1987; 17:899-904
5. Hardie RJ, Lees AJ, Stern GM: On-off fluctuations in Parkinson's disease: A clinical and neuropharmacological study. Brain 1984; 107:487-506
6. Menza MA, Sage J, Marshall E, et al: Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 1990; 5:148-151
7. Maricle RA, Nutt JG, Carter JH: Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findings. Mov Disord 1995; 10:329-332
8. Maricle RA, Nutt JG, Valentine RJ, et al: Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study. Neurology 1995; 45:1757-1760
9. Maricle RA, Valentine RJ, Carter J, et al: Mood response to levodopa infusion in early Parkinson's disease. Neurology 1998; 50:1890-1892
10. Richard IH, Justus AW, Kurlan R: Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13:35-41
11. Damásio AR, Lobo-Antunes J, Macedo C: Psychiatric aspects in parkinsonism treated with 1-dopa. J Neurol Neurosurg Psychiatry 1971; 34:502-507
12. Keshavan MS, David AS, Narayanen HS, et al: "On-off" phenomena and manic-depressive mood shifts: case report. J Clin Psychiatry 1986; 47:93-94
13. Vázquez A, Jiménez-Jiménez FJ, García-Ruiz P, et al: "Panic attacks" in Parkinson's disease. Acta Neurol Scand 1993; 87:14-18
14. Siemers ER, Shekhar A, Quaid K, et al: Anxiety and motor performance in Parkinson's disease. Mov Disord 1993; 8:1-6
15. Goodwin FK: Biochemical and pharmacological studies, in Manic-Depressive Illness, edited by Goodwin FK, Jamison KR. New York, Oxford University Press, 1990, pp 416-502
16. Kaphan E, Witjas T, Azulay JP, et al: Nonmotor fluctuations (NMF) in Parkinson's disease (abstract). Neurology 2001; 56(suppl 3):A121
17. Black KJ, Mink JW: Neuropsychiatry of movement disorders. Curr Opin Psychiatry 1999; 12:313-319
18. Brown RG, Marsden CD, Quinn N, et al: Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1984; 47:454-465
19. Henderson R, Kurlan R, Kersun JM, et al: Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:257-264
20. Friedenberg DL, Cummings JL: Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30:94-99
21. Menza M, Forman N, Sage J, et al: Psychiatric symptoms in Parkinson's disease: A comparison between patients with and without "on-off" symptoms. Biol Psychiatry 1993; 33:682-684
22. Black KJ: Diagnosing depression after stroke. South Med J 1995; 88:699-708
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
24. Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale, in Recent Developments in Parkinson's Disease, edited by Fahn S, Marsden CD, Goldstein M et al. New York, Macmillan, 1987, pp 153-163
25. Quinn N, Critchley P, Marsden CD: Young onset Parkinson's disease. Mov Disord 1987; 2:73-91
26. Torack RM, Morris JC: The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988; 45:497-501
27. Cantello R, Gilli M, Riccio A, et al: Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: A controlled study. J Neurol Neurosurg Psychiatry 1986; 49:1182-1190
28. Potts NL, Book S, Davidson JR: The neurobiology of social phobia. Int Clin Psychopharmacol 1996; 11:43-48
29. Rowe DC, Stever C, Gard JM, et al: The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Genet 1998; 28:215-225
30. Tiihonen J, Kuikka J, Bergstrom K, et al: Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 1997; 154:239-242
31. 2 receptor binding potential in social phobia. Am J Psychiatry 2000; 157:457-459
32. Potts NL, Davidson JR, Krishnan KR, et al: Magnetic resonance imaging in social phobia. Psychiatry Res 1994; 52:35-42
33. Mikkelsen EJ, Detlor J, Cohen DJ: School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. Am J Psychiatry 1981; 138:1572-1576
34. Kormos TC, Meah Y, Miyawaki E, et al: Social phobia in Parkinson's disease (abstract). Mov Disord 1996; 11:601-602
35. Schultz W: Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997; 7:191-197
36. Jackson DM, Westlind-Danielsson A: Dopamine receptors: Molecular biology, biochemistry and behavioral aspects. Pharmacol Ther 1994; 64:291-369
37. 1 dopamine receptors in mediating the antidepressant effect of imipramine. Pharmacol Biochem Behav 1995; 50:147-151
38. 3-type receptors as a final common pathway in antidepressant drug action. Clin Neuropharmacol 1995; 18:S49-S56
39. Bunney WE, Janowsky DS, Goodwin FK, et al: Effect of L-dopa on depression. Lancet 1969; 1:885-886
40. Währens J, Gerlach J: Bromocriptine and imipramine in endogenous depression: A double-blind controlled trial in out-patients. J Affect Disord 1981; 3:193-202
41. Cummings JL: Depression and Parkinson's disease: A review. Am J Psychiatry 1992; 149:443-454
42. Meah Y, Miyawaki E, Kormos TC, et al: Depression in Parkinson's disease: a meta-analysis regarding severity (abstract). Mov Disord 1996; 11:159
43. Mayberg HS, Solomon DH: Depression in Parkinson's disease: A biochemical and organic viewpoint, in Behavioral Neurology of Movement Disorders, edited by Weiner WJ, Lang AE. New York, Raven, 1995, pp 49-60
44. Ring HA, Bench CJ, Trimble MR, et al: Depression in Parkinson's disease: A positron emission study. Br J Psychiatry 1994; 165:333-339
45. Black KJ, Perlmutter JS: Septuagenarian Sydenham's with secondary hypomania. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10:147-150